NewAmsterdam Pharma and the Menarini Group Sign Licensing Deal...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
MIAMI and FLORENCE, Italy and NAARDEN, Netherlands June 28, 2022 /PRNewswire-AsiaNet/ - Combines NewAmsterdam's lead clinical program obicetrapib with Menarini's deep cardiovascular disease and regional expertise - Total deal value of over €1 billion; including €142.5 million upfront payment and committed R&D funding plus potenti...
Authors: LATEST ASIANET NEWS RELEASES